The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3′ processing and transcription termination

  1. Syuzo Kaneko1,3,
  2. Orit Rozenblatt-Rosen2,
  3. Matthew Meyerson2, and
  4. James L. Manley1,4
  1. 1 Department of Biological Sciences, Columbia University, New York, New York, 10027 USA;
  2. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA

Abstract

Termination of RNA polymerase II transcription frequently requires a poly(A) signal and cleavage/polyadenylation factors. Recent work has shown that degradation of the downstream cleaved RNA by the exonuclease XRN2 promotes termination, but how XRN2 functions with 3′-processing factors to elicit termination remains unclear. Here we show that XRN2 physically associates with 3′-processing factors and accumulates at the 3′ end of a transcribed gene. In vitro 3′-processing assays show that XRN2 is necessary to degrade the downstream RNA, but is not required for 3′ cleavage. Significantly, degradation of the 3′-cleaved RNA was stimulated when coupled to cleavage. Unexpectedly, while investigating how XRN2 is recruited to the 3′-processing machinery, we found that XRN2 associates with p54nrb/NonO(p54)–protein-associated splicing factor (PSF), multifunctional proteins involved in several nuclear processes. Strikingly, p54 is also required for degradation of the 3′-cleaved RNA in vitro. p54 is present along the length of genes, and small interfering RNA (siRNA)-mediated knockdown leads to defects in XRN2 recruitment and termination. Together, our data indicate that p54nrb/PSF functions in recruitment of XRN2 to facilitate pre-mRNA 3′ processing and transcription termination.

Keywords

Footnotes

  • 3 Present address: Biochemistry Department, Howard Hughes Medical Institute (HHMI), New York University School of Medicine-Smilow Research Center, New York, NY 10016, USA.

  • 4 Corresponding author.

    4 E-MAIL jlm2{at}columbia.edu; FAX (212) 865-8246.

  • Supplemental material is available at http://www.genesdev.org.

  • Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1565207

    • Received April 26, 2007.
    • Accepted June 12, 2007.
| Table of Contents

Life Science Alliance